Dare Bioscience (NASDAQ: DARE) reported Q2 EPS of ($0.20), $0.11 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $187.55 million versus the consensus estimate of $1.67 thousand.

For earnings history and earnings-related data on Dare Bioscience (DARE) click here.